Anti-tac (daclizumab, zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: A 25-year personal odyssey
Anti-tac (daclizumab, zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: A 25-year personal odyssey
复制标题
DOI：
10.1007/s10875-006-9060-0
复制
发表时间：
2007-01-01
影响因子：
9.1
通讯作者：
Waldmann, Thomas A.
中科院分区：
文献类型：
--
作者：
Waldmann, Thomas A.
25年前，我们报道了单克隆抗体anti-Tac的生产，该抗体识别IL-2受体α亚基并阻断IL-2与该生长因子受体的相互作用。1997年，dlizumab (Zenapax((R))，该抗体的人源化形式，被FDA批准用于预防肾移植排斥反应。此外，我们证明了daclizumab在治疗非感染性葡萄膜炎、多发性硬化症和神经系统疾病人类t细胞嗜淋巴病毒I相关脊髓病/热带痉挛性截瘫（HAM/TSP）患者方面具有价值。其他研究表明，daclizumab对纯红细胞发育不全、再生障碍性贫血和牛皮癣患者有治疗效果。因此，使用单克隆抗体daclizumab获得的关于IL-2/IL-2受体系统的基本见解为预防器官移植排斥和治疗选择性自身免疫性疾病或t细胞白血病/淋巴瘤患者提供了有用的策略。
Twenty-five years ago, we reported the production of the monoclonal antibody, anti-Tac that identifies the IL-2 receptor alpha subunit and blocks the interaction of IL-2 with this growth factor receptor. In 1997, daclizumab (Zenapax((R))), the humanized form of this antibody, was approved by the FDA for use in the prevention of renal allograft rejection. In addition, we demonstrated that daclizumab is of value in the treatment of patients with noninfectious uveitis, multiple sclerosis, and the neurological disease human T-cell lymphotropic virus I associated myelopathy/tropical spastic paraparesis (HAM/TSP). Others demonstrated therapeutic efficacy with daclizumab in patients with pure red cell aplasia, aplastic anemia, and psoriasis. Thus, translation of basic insights concerning the IL-2/IL-2 receptor system obtained using the monoclonal antibody daclizumab provided a useful strategy for the prevention of organ allograft rejection and the treatment of patients with select autoimmune diseases or T-cell leukemia/lymphoma.